Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

10.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results.

JCO oncology advances·2025
Same author

Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024
Same author

Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024
Same author

Pleuroparenchymal fibroelastosis as a late complication of childhood cancer therapy: A case series.

Pediatric blood & cancer·2024
Same author

Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma.

Cancer research·2023
Same author

Comment on: A pooled subgroup analysis of glucarpidase treatment in 86 pediatric, adolescent, and young adult patients receiving high-dose methotrexate therapy in open-label trials.

Pediatric blood & cancer·2023
Same journal

Evolving Therapeutic Strategies in Neuroendocrine Neoplasms: A New Era of Personalized Therapies.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Multiple Chapters, One Career: Using Career Development Plans to Find Success and Satisfaction in Academic Oncology Across the Career Spectrum.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Stepping Up With Immune Checkpoint Blockade: More Combinations and Fewer Contraindications.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Optimal Use of Targeted Therapy and Immunotherapy in Early-Stage, Resectable Non-Small Cell Lung Cancer.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Before the Race Even Starts: Early Intervention to Prevent Long-Term Late Effects From Childhood Cancer Therapies.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Artificial Intelligence in Oncology: Practical Applications Across Clinical Care, Scholarship, and Translation.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
See all related articles

Related Experiment Video

Updated: Apr 12, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

13.0K

Systemic therapy for osteosarcoma and Ewing sarcoma.

Paul A Meyers1

  • 1From Weill Cornell Medical Center, New York, NY, and Memorial Sloan Kettering Cancer Center, New York, NY.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|May 21, 2015
PubMed
Summary
This summary is machine-generated.

Curative treatment for osteosarcoma and Ewing sarcoma needs chemotherapy and local tumor control. For Ewing sarcoma, increasing chemotherapy intensity improves outcomes, while new drug combinations are under investigation.

More Related Videos

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

13.4K
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

19.8K

Related Experiment Videos

Last Updated: Apr 12, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

13.0K
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

13.4K
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

19.8K

Area of Science:

  • Pediatric Oncology
  • Medical Oncology
  • Skeletal System Tumors

Background:

  • Effective treatment for osteosarcoma and Ewing sarcoma relies on combining systemic therapy with local tumor control.
  • Current systemic therapy for osteosarcoma typically involves multiagent chemotherapy, with cisplatin, doxorubicin, and high-dose methotrexate being common.
  • Systemic therapy for Ewing sarcoma utilizes multiagent chemotherapy, often including doxorubicin, vincristine, etoposide, and cyclophosphamide and/or ifosfamide.

Purpose of the Study:

  • To review current systemic therapy approaches for osteosarcoma and Ewing sarcoma.
  • To evaluate the impact of additional agents and dose modifications on treatment outcomes.
  • To discuss ongoing research and future directions in the management of these bone cancers.

Main Methods:

  • Review of existing chemotherapy regimens for osteosarcoma, including standard treatments and additions like ifosfamide, etoposide, interferon, and liposomal muramyl tripeptide.
  • Analysis of systemic therapy for Ewing sarcoma, focusing on dose intensity and novel drug combinations (irinotecan/temozolomide, cyclophosphamide/topotecan).
  • Discussion of high-dose chemotherapy with autologous stem cell rescue for high-risk patients and the need for further trials.

Main Results:

  • For osteosarcoma, adding ifosfamide/etoposide or interferon did not improve outcomes in specific patient groups. Liposomal muramyl tripeptide may enhance survival.
  • Increased chemotherapy dose intensity (shorter intervals or higher doses) improves outcomes in Ewing sarcoma.
  • Certain novel regimens show activity in recurrent/metastatic Ewing sarcoma, with trials ongoing to integrate them into standard care.

Conclusions:

  • Optimizing systemic chemotherapy and local control remains crucial for curative treatment of osteosarcoma and Ewing sarcoma.
  • Dose intensification and exploring novel drug combinations are key strategies for improving Ewing sarcoma outcomes.
  • Further research, including prospective randomized trials, is necessary to confirm the efficacy of new therapeutic strategies, such as high-dose chemotherapy with stem cell rescue.